Abstracts tagged "Coronary Aneurysm"

Abstract Number: 043 • 2020 Pediatric Rheumatology Symposium
Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series
Shelley Shi¹ and Anusha Ramanathan ¹, ¹Kaiser Permanente Los Angeles, Los Angeles, California
Background/Purpose: Treatment for patients with Kawasaki Disease (KD) refractory to standard therapy is controversial. Most experts recommend a second dose of IVIG [1], and for…
Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease Shock Syndrome: A Single Center Cohort
Monica Bray¹, Jennifer Rammel ², Andrea Ramirez ³, Kristen Sexson ⁴, Fong Lam ⁵, Eyal Muscal ¹ and Marietta De Guzman ³, ¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ²Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, ⁵Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 1737 • 2019 ACR/ARP Annual Meeting
Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort
Monica Bray¹, Andrea Ramirez ¹, Eyal Muscal ¹ and Marietta De Guzman ², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease is classically thought to be a monophasic disease that primarily targets the coronary arteries. The American Heart Association Kawasaki guidelines note that…
Abstract Number: 102 • 2017 Pediatric Rheumatology Symposium
Duration of High-Dose Aspirin Therapy Does Not Affect Coronary Artery Outcomes in Kawasaki Disease
Karl Migally¹, Elizabeth A. Braunlin¹, Lei Zhang² and Bryce A. Binstadt³, ¹Pediatric Cardiology, University of Minnesota, Minneapolis, MN, ²Clinical and Translational Sciences Institute, University of Minnesota, Minneapolis, MN, ³Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Kawasaki Disease (KD) is an acute vasculitis targeting the coronary arteries. Prompt treatment with intravenous immunoglobulin (IVIg) reduces the occurrence and potentially the progression…
Abstract Number: 2205 • 2013 ACR/ARHP Annual Meeting
Galectin-3 and Transforming Growth Factor-β Signaling In The Pathogenesis Of Coronary Artery Aneurysms In Kawasaki Disease
Fujito Numano¹, Matthew Vejar², Chisato Shimizu¹, Susan Jimenez-Fernandez¹, Adriana H. Tremoulet³, Jane C. Burns¹ and Lori B. Daniels², ¹Pediatrics, UC San Diego, School of Medicine, La Jolla, CA, ²Departments of Medicine, UC San Diego, School of Medicine, La Jolla, CA, ³Department of Pediatrics, UC San Diego, School of Medicine, La Jolla, CA
Background/Purpose: Kawasaki disease (KD) is a self-limited acute vasculitis of young children, and coronary artery aneurysms (CAA) are the most significant complication. Despite appropriate treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].